INS and metabolic syndrome: Promotion of Dyslipidemia and Insulin Resistance in MASLD: In patients with MASLD, factors including lipotoxicity and meta-inflammation result in dysregulated hepatic lipid metabolism and decreased hepatic insulin sensitivity, leading to dyslipidemia, as well as increased glycogenolysis and gluconeogenesis resulting in hyperglycemia, significant risk factors for atherosclerosis [31].